Congress Materials

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Jacob P. Thyssen, Anthony Bewley, Sonja Ständer, Carla Castro, Laurent Misery, Brian S. Kim, Jonathan I. Silverberg, Pinaki Biswas, Gary Chan, Daniela E. Myers, Melissa Watkins, Justine Alderfer, Erman Guler May 1, 2023 RAD Apr 2023 Atopic Dermatitis

Effect of abrocitinib versus dupilumab on skin pain: an analysis of the phase 3 JADE COMPARE and JADE DARE trials

View Presentation
Poster
Lawrence F. Eichenfield, Carsten Flohr, Christine Bangert, Alan D. Irvine, Stephan Weidinger, John Nesnas, Herwig Koppensteiner, Fan Zhang, Ricardo Rojo, Gary Chan May 1, 2023 RAD Apr 2023 Atopic Dermatitis

Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis (AD) from the JADE clinical trial program

View Presentation
Oral Presentation
Amy S. Paller, Lawrence F. Eichenfield, Jonathan I. Silverberg, Michael J. Cork, Christine Bangert, Alan D. Irvine, Stephan Weidinger, Sébastien Barbarot, Haiyun Fan, Justine Alderfer, Herwig Koppensteiner, Kanti Chittuluru May 1, 2023 RAD Apr 2023 Atopic Dermatitis

Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure

View Presentation
Oral Presentation
Andrew F. Alexis, Mette Deleuran, Jonathan I. Silverberg, Melinda Gooderham, Saleem A. Farooqui, Gary Chan, Herwig Koppensteiner, Pinaki Biswas, Melissa Watkins May 1, 2023 RAD Apr 2023 Atopic Dermatitis

Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial

View Presentation